Angiochem to Present New Clinical Data for ANG1005 in Brain Cancers at Society for Neuroscience Meeting

ANG1005 and Angiochem`s EPiC platform to be Highlighted at Conference
MONTREAL & CHICAGO--(Business Wire)--
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are
uniquely capable of crossing the blood-brain barrier to treat brain diseases,
announced today that clinical data for its lead drug candidate, ANG1005, for the
treatment of brain cancers, as well as data showing how compounds from
Angiochem`s Engineered Peptide Compounds (EPiC) platform are capable of crossing
the blood-brain barrier will be highlighted at the Society for Neuroscience
Annual Meeting in Chicago on October 17-21, 2009. In addition to poster
presentations, ANG1005 and Angiochem`s EPiC platform will be the subject of a
Society for Neurosciences-sponsored press conference, entitled "Crossing the
Blood-Brain Barrier." Angiochem will also be sponsoring a scientific symposia
discussing new therapeutic approaches to crossing the blood-brain barrier.

ANG1005 is a novel, next-generation taxane derivative, targeting the LRP pathway
to cross the blood-brain barrier and reach therapeutic concentrations in the
brain. ANG1005 is in two separate Phase 1/2 clinical studies in patients with
brain cancers and cancer metastases. The drug was created with Angiochem`s
Engineered Peptide Compound (EPiC) platform which harnesses the
naturally-occurring LRP (low-density lipoprotein receptor-related protein)
receptors on the surface of the blood-brain barrier.

The schedule is as follows:

* Society for Neuroscience Press Conference: Sunday, October 18, 2009, 11:00
a.m., "Crossing the Blood-Brain Barrier", McCormick Place Conference Center,
South 501D.
* Poster Presentation #185.1: Sunday, October 18, 8 a.m. - 12 p.m., "Development
Of A New Engineered Peptide Compound (EPiC) Platform For The Transport Of Small
And Large Therapeutics To The CNS", Gabathuler, et.al., McCormick Place
Conference Center, South Hall A.
* Poster Presentation #185.6: Sunday, October 18, 8 a.m. - 12 p.m., "Development
Of A New Engineered Peptide Compound (EPiC) For The Treatment Of Malignant
Glioma", Drappatz, et.al., McCormick Place Conference Center, South Hall A.
* Poster Presentation #185.2: Sunday, October 18, 8 a.m. - 12 p.m., "ANG1005: A
promising new Engineered Peptide Compound (EPiC) for patients with advanced
solid tumors and brain metastases", Kurzrock, et. al., McCormick Place
Conference Center, South Hall A.
* Scientific Breakfast Symposia: Monday, October 19, 6:30 - 8:30 a.m., "Crossing
The Blood-Brain Barrier: New Therapeutic Approaches", Hyatt Regency McCormick
Place, Room CC10CD - Level 1. This scientific symposia includes presentations
and Q&A with leading scientific, medical and industry experts in the areas of
CNS and oncology. The event will also be webcast and available on the Angiochem
website at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=232273&eventID=2482177

About ANG1005 // ANG1005 is a novel, next-generation taxane derivative targeting
the LRP pathway. ANG1005 was engineered with the EPiC platform which was
designed to cross the blood-brain barrier (BBB). Studies have shown that ANG1005
gains entry into the brain compartment by targeting the low-density lipoprotein
receptor-related protein (LRP) which is one of the most highly expressed
receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor
cells using the same receptor-mediated pathway through LRP, which is upregulated
in various cancer cells including gliomas and metastatic brain cancers.

About Angiochem // Angiochem is a clinical-stage biotechnology company
discovering and developing new breakthrough drugs that are uniquely capable of
crossing the blood-brain barrier (BBB) to treat brain diseases. The company`s
proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that
cross the BBB and reach therapeutic concentration in the brain, by harnessing
naturally-occurring receptors on the surface of the BBB. Angiochem`s lead
product candidate, ANG1005 is in two separate Phase 1/2 clinical studies in
patients with brain cancers and cancer metastases. Additionally, Angiochem is
developing a deep and broad product pipeline, including small and large
molecules, for the potential treatment of a wide range of CNS diseases,
including neurodegenerative and metabolic diseases, brain cancer, psychiatric
disorders and many others. Founded in 2006, Angiochem maintains headquarters in
Montreal, Canada. For additional information about the Company, please visit
http://www.angiochem.com.

Copyright 2009 Angiochem, Inc.

Media Contact:
Yates Public Relations
Kathryn Morris, 845-635-9828
or
Investor Contact:
Yates Public Relations
Gina Nugent, 617-460-3579
or
Business Development Contact:
Angiochem, Inc.
Queenie Jang, 604-263-7877

Copyright Business Wire 2009